Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial
- Resource Type
- Authors
- Cynthia Z. Qi; Andy Garnham; Hongbo Yang; Amer M. Zeidan; Manasee V. Shah; Bhavik J. Pandya
- Source
- Leukemia & Lymphoma. 63:762-764
- Subject
- Salvage Therapy
Oncology
Cancer Research
medicine.medical_specialty
Aniline Compounds
business.industry
Salvage treatment
Gilteritinib
Myeloid leukemia
Hematology
Newly diagnosed
Leukemia, Myeloid, Acute
fms-Like Tyrosine Kinase 3
Pyrazines
hemic and lymphatic diseases
Secondary analysis
Internal medicine
Tyrosine Kinase 3
Mutation
Number needed to treat
Humans
Medicine
business
- Language
- ISSN
- 1029-2403
1042-8194
Approximately 30% of patients newly diagnosed with acute myeloid leukemia (AML) have FMS-like tyrosine kinase 3 mutations (FLT3mut+), conferring a negative effect on prognosis with a high likelihoo...